On August 27, 2021 Scandion Oncology A/S reported that the company has obtained approval from the German regulatory authorities to initiate clinical trials in Germany with SCO-101 in the PANTAX Ib study (Press release, Scandion Oncology, AUG 27, 2021, View Source,c3404242 [SID1234586967]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The German medicines agency (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) and the German ethics committee have given approval, allowing Scandion Oncology to expand the PANTAX Ib study to Germany.

"We are very pleased to receive this German approval as BfArM is highly regarded and known for having tough critera. The approval is important for the PANTAX Ib study, but it also opens the door to starting trials in Germany with SCO-101 in other indications. We will communicate more about our plans and strategy at our Capital Markets Day on September 8," said Bo Rode Hansen, President & CEO of Scandion Oncology.

On August 27, 2021 BeiGene (NASDAQ:BGNE) and Immix Biopharma reported a clinical trial and supply agreement to evaluate the safety, tolerability and efficacy of a combination of IMX-110 and tislelizumab for the treatment of various solid tumors (Press release, Immix Biopharma, AUG 27, 2021, View Source [SID1234587963]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, ImmixBio will evaluate the combination of IMX-110 with tislelizumab in a Phase 1/2a trial in patients with advanced solid tumors.

"We have high hopes that IMX-110 in combination with tislelizumab could expand the population of cancer patients experiencing extended remissions," ImmixBio CEO Ilya Rachman said.

On August 27, 2021 Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, reported that the abstract "A pilot study of Engineered Adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma" will be presented as an e-poster at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) congress by Dr Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center (Press release, Targovax, AUG 27, 2021, View Source [SID1234586968]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

E-poster title:

A pilot study of Engineered Adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma

E-poster number:

1083P

Presenter: Dr Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center
The abstract will be released on the ESMO (Free ESMO Whitepaper) website 13 September 00:05 CEST (View Source). The results from the completed phase 1 trial will be presented during the ESMO (Free ESMO Whitepaper) congress 16-21 September 2021.

About ESMO (Free ESMO Whitepaper)

ESMO is the leading professional organisation for medical oncology. With more than 23,000 members representing oncology professionals from over 150 countries worldwide, ESMO (Free ESMO Whitepaper) is the society of reference for oncology education and information. ESMO (Free ESMO Whitepaper) is committed to offer the best care to people with cancer, through fostering integrated cancer care, supporting oncologists in their professional development, and advocating for sustainable cancer care worldwide.

On August 27, 2021 Genmab A/S (Nasdaq: GMAB) reported that its CEO, Jan van de Winkel, Ph.D. will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference at 8:00 AM EDT / 2:00 PM CEST on September 9, 2021b (Press release, Genmab, AUG 27, 2021, View Source [SID1234586970]). A webcast of the event, which will include brief opening remarks followed by a question-and-answer session, will be available on Genmab’s website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 27, 2021 Lynk Pharmaceuticals reported that it completed a Series B financing of $50 million to conduct Phase I/II clinical trials of its pipeline products and expand its international business (Press release, Lynk Pharmaceuticals, AUG 27, 2021, View Source [SID1234586971]). Founded in 2018 by veteran drug hunters with experience working for Pfizer, Merck and Johnson & Johnson, Lynk is developing FIC/BIC small molecule drugs for autoimmune diseases, inflammation and cancer. The financing was led by Lilly Asia Ventures, plus New Alliance Capital and Hangzhou HEDA Biological Medicine as co-investors

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!